Novavax has begun a late-stage trial of its experimental COVID-19 vaccine in the UK, which could support filings for a licence in the UK, EU and other countries.

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

A number of High Street chemists and private clinics sell and administer the Pfizer Covid vaccine directly to the public. The ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

Novavax, Inc. (NYSE:NVAX ... received clearance from the U.S. FDA to proceed with a Phase 3 immunogenicity trial for both the CIC and standalone influenza vaccine candidates.

Analyst Vernon Bernardino of H.C. Wainwright reiterated a Buy rating on Aethlon Medical (AEMD – Research Report), retaining the price target of ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...